-
InnoCare Pharma Reports 29.8% Revenue Increase in Q3 2024 Financials
•
Beijing-based biotech InnoCare Pharma (HKG: 9969; SHA: 688428) has released its financial report for the third quarter of 2024, ending September 30, 2024, along with operational updates. The company reported revenue of RMB 698 million (USD 96.9 million) for the first three quarters, marking a 29.8% increase over the same…
-
InnoCare Pharma’s ICP-488 Shows Promising Results in Phase II Psoriasis Study
•
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II clinical study for its TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, ICP-488, in patients with moderate to severe plaque psoriasis. The study demonstrated the drug’s potential in treating psoriasis and other autoimmune diseases by inhibiting…
-
InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment
•
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II clinical study for its TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, ICP-488, in patients with moderate to severe plaque psoriasis. ICP-488 is a potent and selective TYK2 allosteric inhibitor that is being developed to treat…
-
InnoCare Pharma’s Orelabrutinib Achieves Milestone in SLE Clinical Trial Enrollment
•
InnoCare Pharma announced on October 4, 2024, that it has completed patient enrollment in a Phase II clinical trial for its novel BTK inhibitor, Orelabrutinib, for the treatment of Systemic Lupus Erythematosus (SLE). This randomized, double-blind, placebo-controlled, multicenter Phase IIb clinical study is designed to evaluate the efficacy and safety…
-
InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its financial report for the first half of 2024, highlighting a revenue of RMB 4.197 billion, marking an increase of 11.2% year-on-year. This growth was primarily driven by the rapid adoption of its key product, orelabrutinib,…
-
InnoCare Pharma’s TYK2 Inhibitor ICP-332 Receives FDA IND Approval for Atopic Dermatitis
•
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company based in China has announced that the US Food and Drug Administration (FDA) has granted Investigational New Drug (IND) approval for its TYK2 inhibitor, ICP-332. This development marks a significant step forward for the company as it seeks to expand its…
-
InnoCare’s Tafasitamab-Lenalidomide Combo on Track for Priority Review in China for DLBCL Treatment
•
The Center for Drug Evaluation (CDE) website has indicated that InnoCare (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, is on track to receive priority review status for its drug candidate Minjuvi (tafasitamab) in combination with lenalidomide. This treatment is intended for adult patients with recurrent or refractory…
-
InnoCare Pharma Reports 2023 Revenue Growth and Pipeline Expansion
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has released its financial report for 2023, recording RMB 739 million (USD 102.2 million) in revenues and RMB 672 million (USD 92.9 million) in product sales, marking increases of 18.09% and 18.5% year-on-year (YOY), respectively. The company’s research and development…
-
InnoCare Pharma Initiates Phase Ib Study Combining ICP-189 with Furmonertinib for NSCLC
•
InnoCare Pharma (HKG: 9969, SHA: 688428), a biopharmaceutical company , has announced that the first patient has been dosed in a Phase Ib clinical study. The study is evaluating the combination of InnoCare’s SHP2 allosteric inhibitor, ICP-189, with the selective EGFR inhibitor furmonertinib for the treatment of advanced or metastatic…
-
InnoCare Pharma Receives IND Approval in China for BCL2 Inhibitor Combo Therapy
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a Beijing-based biotech company, has announced that it has received approval for an Investigational New Drug (IND) clinical trial filing in China. The company is set to initiate a clinical trial for its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with its Bruton’s…
-
China Anti-Cancer Association Forms Consortium for Standardizing Cancer Research Ethics Reviews
•
The medical ethics professional committee of the China Anti-Cancer Association (CACA) has announced the formation of the China Cancer Clinical Research Medical Ethics Review Mutual Recognition Consortium. This consortium aims to streamline and standardize the ethical review process for clinical research in cancer treatment across China. The founding members of…
-
InnoCare Pharma Receives US FDA IND Approval for BCL2 Inhibitor ICP-248
•
InnoCare Pharma (HKG: 9969; SHA: 688428), a China-based pharmaceutical company, has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its B-cell lymphoma-2 (BCL2) inhibitor, ICP-248. The drug is set to enter a Phase I trial to assess safety, tolerability,…
-
InnoCare’s TYK2 Inhibitor ICP-332 Shows Positive Results in Atopic Dermatitis Phase II Study
•
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a Chinese biotechnology company specializing in oncology and autoimmune diseases, has reported positive outcomes from a Phase II clinical trial for its tyrosine kinase 2 (TYK2) inhibitor, ICP-332. The randomized, double-blind, placebo-controlled study is investigating the efficacy of ICP-332 in patients with moderate…
-
InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment
•
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced that it has received the green light to conduct a clinical study in China for its drug candidate ICP-189, in combination with ArriVent Biopharma Inc.’s furmonertinib, for the treatment of advanced non-small cell lung cancer (NSCLC). The collaboration between InnoCare and…
